Combined imaging markers increase accuracy when predicting real life disease onset in Huntington’s disease
Objective: To identify a robust imaging marker that is capable of predicting real life disease onset in Huntington's disease (HD). Background: Huntington's disease (HD) is…Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice
Objective: To investigate the effects of the exposure to low-dose rotenone of heterozygous PINK1 knockout (PINK1+/-) mice, compared to their wild-type littermates (PINK1+/+), on dopamine-dependent…Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease
Objective: Identify magnetic resonance imaging (MRI) biomarkers of nigrostriatal neurodegeneration in early-stage drug-naïve Parkinson's disease (PD). Background: Diffusion tensor imaging (DTI) is an MRI technique…Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease
Objective: To assess the therapeutic potential of chronic vagus nerve stimulation (VNS) to attenuate the behavioral and neuronal deficits observed in Parkinson's disease (PD) by…Role of dopamine and GABA during subthalamic and pallidal deep brain stimulation: Evidence of dopamine release during subthalamic Deep Brain Stimulation
Objective: We recorded the single-unit activity of striatal cholinergic interneurons of healthy monkeys during high-frequency stimulation (HFS) of the subthalamic nucleus (STN) and globus pallidus…Dissecting the molecular mechanisms of Fyn-mediated levodopa induced dyskinesias
Objective: To investigate the crosstalk between D1 receptor (D1R) and the signaling of Fyn protein kinase in a mice model of levodopa (L-DOPA) induced dyskinesias…A whole brain anatomical network model and its application in PD research
Objective: To build a frame of whole brain anatomical network for incorporating different data from different studies with different brain parcellations and resolutions, to evaluate…Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…
- « Previous Page
- 1
- …
- 6
- 7
- 8